SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical OfficerBusiness Wire • 05/31/22
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based ProcessBusiness Wire • 05/18/22
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio UpdatesBusiness Wire • 05/10/22
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022Business Wire • 05/05/22
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical ResearchBusiness Wire • 05/05/22
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ TumorsBusiness Wire • 04/27/22
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In VivoBusiness Wire • 04/11/22
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform's Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 DiabetesBusiness Wire • 04/04/22
SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson's DiseaseBusiness Wire • 03/21/22
SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio UpdatesBusiness Wire • 03/16/22
SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual MeetingBusiness Wire • 03/08/22
SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC's Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell ActivationBusiness Wire • 02/01/22
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid TumorsBusiness Wire • 01/24/22
SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic AdvisorBusiness Wire • 01/06/22
SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor PatientBusiness Wire • 12/09/21
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid TumorsBenzinga • 12/02/21
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest DoseBusiness Wire • 12/02/21
SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx ConferenceBusiness Wire • 11/29/21
SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare ConferenceBusiness Wire • 11/15/21
SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual MeetingBusiness Wire • 11/12/21
SQZ Biotechnologies Reports Third Quarter 2021 Financial Results and Recent Portfolio UpdatesBusiness Wire • 11/10/21
SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate Into Combination With Checkpoint InhibitorsBusiness Wire • 10/26/21
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual MeetingBusiness Wire • 10/04/21
SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines ConferenceBusiness Wire • 09/30/21
